JC
Schedule 13G filing
JPMORGAN CHASE & CO disclosed a 5.5% stake in Lexeo Therapeutics, Inc. (LXEO)
JPMORGAN CHASE & CO reported owning 5.5% of Lexeo Therapeutics, Inc. (LXEO) (4,573,701 shares) in a Schedule 13G filed Oct 13, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 13, 2026
- Source
- Schedule 13G
More LXEO insider and Congress trades
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.